Sirna Delivery
Sirna Delivery - Related Videos
10:33
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
0 Views •
Cited by 18 •
2016
The goal of this protocol is to use cationic/anionic liposomes with a neuro-targeting peptide as a CNS delivery system to enable siRNA to cross the BBB. The optimization of a delivery system for treatments, like siRNA, would allow for more treatment options for prion and other neurodegenerative diseases.
04:05
Intranasal Delivery of siRNA to the Mouse Brain Using a Positioning Device
0 Views •
2025
Source: Ullah, I., et.al. A Positioning Device for the Placement of Mice During Intranasal siRNA Delivery to the Central Nervous System. J. Vis. Exp. (2019)This video demonstrates a precise intranasal administration technique for delivering neuron-targeting peptide-siRNA complexes to the mouse brain using a specialized positioning device. Anesthetized mice are secured in a head-down-and-forward position to optimize siRNA inhalation while preventing lung drainage. The targeting peptide...
02:57
Targeted siRNA Delivery to Neurons for Prion Protein Silencing Using Liposomal Complexes
0 Views •
2025
Source: Bender, H. R., et.al. Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes. J. Vis. Exp. (2016)This video demonstrates the targeted delivery of prion protein (PrP) siRNA to neurons using liposomal siRNA-peptide complexes (LSPCs). Cationic liposomes electrostatically bind PrP-targeting siRNA, which is further stabilized by the RVG-9r peptide for receptor-mediated transport across the blood-brain barrier. Once inside the brain, LSPCs undergo endocytosis in...
03:04
siRNA Encapsulation into Exosomes Using Electroporation: An Electric Pulse Based Technique to Load siRNA into Exosomes
0 Views •
2023
This video describes an electroporation-based method for encapsulating siRNA into exosomes. The siRNA-loaded exosomes can then be used for therapeutic applications.
02:30
siRNA - Small Interfering RNAs
0 Views •
2020
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements. In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
FAQs
Once siRNA reaches the cytoplasm, it becomes associated with the RNA-induced silencing complex. The guide strand within this complex provides the sequence-specific recognition signal, allowing the complex to identify complementary messenger RNA and promote its cleavage. This molecular matching is what connects delivery to selective gene-expression reduction rather than a general loss of cellular RNA.
Cytoplasmic release places siRNA in the cellular compartment where the RNA-induced silencing complex can use it. A delivery system must therefore do more than support cellular entry: it must also enable release of the RNA after uptake. If release is inadequate, the transported material may not effectively participate in sequence-specific messenger RNA recognition and cleavage.
These delivery approaches address several barriers faced by siRNA molecules. They can help protect the RNA from degradation, promote cellular uptake, influence tissue distribution, and support release inside cells. Their importance lies in coordinating these functions, because protection alone does not ensure access to the cytoplasm, and uptake alone does not guarantee productive gene silencing.
The outcome depends on how well a system preserves siRNA, transports it to relevant cells or tissues, and releases it where the silencing machinery can act. Degradation reduces the available RNA, limited uptake restricts cellular access, and poor release prevents effective cytoplasmic activity. These variables help determine whether sequence-specific messenger RNA cleavage produces a useful reduction in gene expression.
A typical workflow begins by associating siRNA with a protective delivery system, such as a lipid nanoparticle, polymer, or conjugated molecule. The system then supports transport toward target cells, cellular uptake, and release of the RNA. After cytoplasmic entry, the siRNA engages the RNA-induced silencing complex, which directs recognition and cleavage of complementary messenger RNA.
In molecular biology, the approach supports functional gene studies by reducing expression of a selected gene and allowing researchers to examine the resulting consequences. Its value comes from linking sequence-specific messenger RNA cleavage with an observable change in gene activity. Delivery systems expand this use by helping siRNA reach cells in which the target gene is being investigated.
Therapeutic research can use this strategy to investigate diseases associated with aberrant or harmful gene activity. By directing siRNA toward complementary messenger RNA, researchers can evaluate whether reducing expression of a relevant gene produces a useful outcome. Delivery design remains central because protection, cellular uptake, tissue distribution, and intracellular release influence whether the intended silencing effect can be reached.